Stock listing
Maia Biotechnology, Inc.
Selected listing: MAIA · AMEX · USD · US
Maia Biotechnology, Inc. (NYSE American: MAIA), Health Technology. Latest release Sep 16, 2026: MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2…
- Ticker
- NYSE American: MAIA
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NYSE American
- Currency
- USD
About Maia Biotechnology, Inc.
Maia Biotechnology, Inc. is a public company traded under the ticker MAIA in the American market. Maia focuses on developing innovative therapies in the biotechnology sector.
Latest news from Maia Biotechnology, Inc.
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
September 16, 2026
MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
September 15, 2026
MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026
September 10, 2026
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
July 8, 2026
MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
June 25, 2026
Research Maia Biotechnology, Inc.
Maia Biotechnology, Inc. company profile
View the public company page for Maia Biotechnology, Inc. on 6ix.
Maia Biotechnology, Inc. news
Read company news and market updates connected to Maia Biotechnology, Inc..
Maia Biotechnology, Inc. investor events
Find investor webinars, events, and replay context for Maia Biotechnology, Inc..